Glimisave M3 850 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 3 mg and Metformin 850 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The extended-release formulation of Glimisave M3 850 allows for sustained drug release, promoting stable plasma concentrations and enhancing patient compliance through once-daily dosing. This combination is particularly beneficial for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve optimal glycemic targets. It is essential to monitor renal function prior to and during therapy due to the risk of lactic acidosis associated with Metformin. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Glimisave M3 850 should be used cautiously in patients with hepatic impairment, cardiovascular disease, or conditions predisposing to hypoxia. Regular blood glucose monitoring and adherence to prescribed lifestyle modifications are recommended to maximize therapeutic outcomes.